David G. Mutch

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Correction: GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress

  Molecular Cancer Research · 2026-03-03

• Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology

  Journal of the National Comprehensive Cancer Network · 2025-12-01 · 13 citations

• Supplementary Figure S1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

  2025-11-25

• Supplementary Table 4 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

  2025-11-25

• Supplementary Table 5 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

  2025-11-25

• Supplementary Figure S3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

  2025-11-25

• Supplementary Figure S4 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

  2025-11-25

• Supplementary Table 2 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

  2025-11-25

• Supplementary Table 3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

  2025-11-25

• Supplementary Table 1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

  2025-11-25

• Supplementary Figure S2 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

  2025-11-25

• AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer

  Gynecologic Oncology · 2025-11-21

• Targeting RAD52 overcomes PARP inhibitor resistance in preclinical <i>Brca2</i> -deficient ovarian cancer modelPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-09-26

• Supplementary Tables from Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy–Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response

  2025-09-15

• Supplemental Figure 1 from Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy–Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy ResponsePreprint

  2025-09-15

• Data from Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy–Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response

  2025-09-15

• Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol

  Gynecologic Oncology · 2025-09-03

• COPS5 depletion via CSN5i-3 downregulates DNA damage repair to synergize with poly (ADP-ribose) polymerase inhibitors

  Gynecologic Oncology · 2025-09-01

• Ineffective nonsense-mediated decay in high-grade serous ovarian cancer: An unappreciated driver of tumor behavior

  Gynecologic Oncology · 2025-09-01

• Targeting the COP9 signalosome overcomes platinum resistance in ovarian cancer through two distinct genome stability mechanismsPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-08-06